Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Adimab

Adimab
2007 FOUNDED
PRIVATE STATUS
101-200 EMPLOYEES
Series F LATEST DEAL TYPE
$13.8M LATEST DEAL AMOUNT
8 INVESTORS
Description

Producer of yeast-based therapeutic human antibodies designed to offer unprecedented quality and speed from target to therapeutic lead. The company's therapeutic human antibodies involves in the discovery, maturation and production of yeast-based immunoglobulin, enabling healthcare professionals to treat cancer as well as autoimmune and infectious diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 7 Lucent Drive
  • Lebanon, NH 03766
  • United States

+1 (603) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Adimab’s full profile, request a free trial.

Adimab Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series F) 16-Apr-2012 $13.8M 000.00 00000 Completed Profitable
5. Later Stage VC (Series E) 30-Jan-2010 000 000.00 00000 Completed Profitable
4. Later Stage VC (Series D) 01-Oct-2009 00.000 000.00 00000 Completed Profitable
3. Later Stage VC (Series C) 20-Nov-2008 00.000 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 25-Mar-2008 $3.18M $9.5M 000.00 Completed Startup
1. Early Stage VC (Series A) 20-Jul-2007 $6.32M $6.32M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Adimab Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000 00.000000 000.00 0000.00 00 000.00 0.000
Series D 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series C 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series A2 1,574,133 $0.001000 $3.76 $3.76 1x $3.76 22.67%
Series A1 300,000 $0.001000 $1.33 $1.33 1x $1.33 4.32%
To view this company’s complete Cap Table, request access »

Adimab Competitors (67)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidity Biosciences Venture Capital-Backed La Jolla, CA 00000 00000000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000 (0000000000000 Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Adimab Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 26-Jul-2007 000000000000000000 Biotechnology 0000000 000000000 00.0
To view this company’s complete investment and acquisition history, request access »

Adimab Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
LaunchCapital Venture Capital Minority 000 0000 000000 0
Mithril Capital Management Venture Capital Minority 000 0000 000000 0
Georges Harik Angel (individual) Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Borealis Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Adimab Executive Team (13)

Name Title Board
Seat
Contact
Info
Kirt Johnson Associate Director of Product Engineering
Kristin Rookey Director, Alliance Management and Business Development
Mary Schiavoni Head, Human Resources
Karl Wittrup Ph.D Co-Founder, Office of the CSO, Chairman of the SAB
Eric Krauland Ph.D Vice President, Antibody Discovery & Optimization

3 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Adimab Board Members (10)

Name Representing Role Since Contact
Info
Ajay Royan Mithril Capital Management Board Member 000 0000
Carl Gordon Ph.D OrbiMed Board Member 000 0000
Errik Anderson Self Co-Founder 000 0000
Karl Wittrup Ph.D Adimab Co-Founder, Office of the CSO, Chairman of the SAB 000 0000
Michael Ross Ph.D SV Health Investors Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »